TGA Compliance Priorities 2026-2027: What Healthcare Businesses Need to Know

The Therapeutic Goods Administration (TGA) has published its compliance priorities for the 2026-2027 period, and the message is clear: digital marketing of therapeutic goods in Australia is under closer scrutiny than at any point in the regulator's history.

For healthcare businesses, clinics, and practitioners who market therapeutic goods or services involving therapeutic goods, these priorities represent a meaningful shift in how the TGA approaches compliance. The regulator is modernising its monitoring capabilities, expanding its focus on online activity, and signalling that enforcement will be swifter and more visible.

After working with healthcare businesses across Australia for over a decade, including medicinal cannabis clinics, weight loss providers, cosmetic surgery practices, and allied health providers, we have seen how regulatory changes can catch businesses off guard when they are not paying attention. This guide breaks down what the TGA's new priorities mean in practical terms and what healthcare businesses should be doing now to stay ahead of them.

Understanding the TGA's Five Compliance Principles

The TGA has structured its 2026-2027 compliance approach around five overarching principles. These are not just abstract policy statements. Each one has direct implications for how healthcare businesses can and should be marketing their products and services.

1. Safeguarding Therapeutic Goods

The TGA is taking a proactive stance on advertising scrutiny, particularly in digital channels. This means the regulator is not waiting for complaints before investigating. It is actively monitoring digital advertising, e-commerce platforms, and social media for non-compliant promotion of therapeutic goods.

For healthcare businesses, this is a significant shift. Previously, many businesses operated on the assumption that TGA enforcement was primarily complaint-driven. The move to proactive surveillance means that non-compliant advertising on your website, social media profiles, Google Ads campaigns, or marketplace listings could attract regulatory attention without anyone lodging a formal complaint.

This principle also targets unapproved and falsified goods being sold through e-commerce and social media channels. If your business operates in a space where unapproved alternatives exist (medicinal cannabis, weight loss products, and cosmetic injectables are prime examples), expect the TGA to be watching these channels closely.

2. Educate to Empower

The TGA is investing in education for consumers, health professionals, and industry participants. More importantly for marketing purposes, this principle includes a commitment to countering misinformation and disinformation online, specifically calling out social media and influencer content.

This has real implications for content marketing strategies. Healthcare businesses that publish educational content about their products or services need to ensure that content is accurate, balanced, and does not stray into territory the TGA might classify as misinformation. This applies to blog articles, social media posts, video content, podcasts, and any other content your business produces.

The specific mention of influencer content is notable. If your business works with influencers, brand ambassadors, or affiliates who create content about your products, the TGA is signalling that this content falls squarely within its regulatory scope.

3. Protect Those Most at Risk

The TGA is developing targeted strategies for at-risk populations and collaborating with community leaders to ensure health information is culturally appropriate and accessible.

For healthcare businesses, this principle means paying attention to how your marketing reaches and affects vulnerable populations. If your services or products are used by elderly Australians, people with chronic conditions, culturally and linguistically diverse communities, or other groups the TGA might consider at-risk, your marketing needs to be especially careful about accuracy and accessibility.

This is particularly relevant for businesses marketing weight loss medications, listed medicines, and complementary health products, where vulnerable consumers may be more susceptible to misleading claims.

4. Leverage Digital Capability

The TGA is modernising its compliance monitoring tools and enhancing its ability to monitor online activity. Two specific callouts stand out: AI-generated misinformation and deceptive endorsements.

This is the principle that should give every healthcare marketer pause. The TGA is building capability to detect and act on AI-generated content that makes misleading claims about therapeutic goods. If your business uses AI tools to generate marketing copy, social media posts, or website content (and many businesses do in 2026), you need robust review processes to ensure that AI-generated content does not include claims that breach TGA requirements.

The focus on deceptive endorsements encompasses paid testimonials, undisclosed sponsorships, and fake reviews. If your business has any arrangement where people are compensated (whether financially or with free products) for endorsing your therapeutic goods, these arrangements need to be transparent and compliant.

5. Strengthen Enforcement

The TGA is committing to swift, proportionate action on emerging trends, with increased visibility of compliance actions. The regulator is specifically targeting non-compliance via digital channels, including influencers and online marketplaces.

The visibility aspect is worth noting. The TGA is signalling that it will publicise enforcement actions more prominently. For healthcare businesses, this means the reputational consequences of non-compliance are amplified. A compliance action that might previously have been resolved quietly could now become public, with implications for your brand, patient trust, and business relationships.

The 12 Priority Focus Areas: What They Mean for Your Business

Effective from 1 January 2026 (with the next review in March 2026), the TGA has identified 12 specific product categories for priority compliance attention. Not all of these will be relevant to every healthcare business, but several are directly connected to healthcare marketing activities.

Medicinal Cannabis: Under the Spotlight

Medicinal cannabis has been on the TGA's radar for some time, but its inclusion as a priority focus area in 2026-2027 signals intensified scrutiny. The sector has experienced rapid growth in Australia, and with that growth has come a proliferation of digital marketing that pushes regulatory boundaries.

The core issue is that medicinal cannabis remains a prescription medicine in Australia. Advertising prescription medicines directly to consumers is prohibited under the Therapeutic Goods Act. Yet many medicinal cannabis businesses operate marketing strategies that come very close to, or arguably cross, that line.

Common areas of concern include websites that emphasise specific conditions treatable with medicinal cannabis, social media content that promotes the benefits of cannabis products, influencer partnerships where content creators discuss their positive experiences with medicinal cannabis, and Google Ads campaigns targeting condition-related searches and directing users to cannabis clinic landing pages.

For medicinal cannabis businesses, the path forward requires careful attention to the distinction between educating consumers about the existence of legal pathways to access medicinal cannabis and directly promoting specific cannabis products or making therapeutic claims.

Weight Loss Medications: The GLP-1 Marketing Surge

The explosion of interest in GLP-1 receptor agonist medications for weight loss has created a corresponding surge in marketing activity. Telehealth weight loss clinics, compounding pharmacies, and other providers have invested heavily in digital advertising to capture demand.

The TGA's focus on weight loss medications reflects concerns about how these products are being marketed. Prescription weight loss medications cannot be advertised to consumers, yet social media is saturated with content that effectively promotes specific medications, often using before-and-after imagery and personal endorsements that would be non-compliant if published by the manufacturer or prescriber.

Businesses operating in the weight loss space need to distinguish carefully between marketing weight management services (which can be advertised, subject to standard healthcare advertising rules) and promoting specific prescription medications (which cannot). The line between these two activities has been blurred by many operators, and the TGA's priority focus suggests enforcement is coming.

Therapeutic Goods Used in Cosmetic Procedures

This category captures the products used in cosmetic procedures, including dermal fillers, anti-wrinkle injectables, and other therapeutic goods administered in cosmetic settings. For cosmetic clinics and practitioners, this priority area intersects with existing AHPRA advertising requirements to create a particularly strict regulatory environment.

The TGA's concern centres on how these products are marketed. Many cosmetic clinics promote specific products by brand name, make claims about product efficacy, or use before-and-after imagery that attributes results to particular products. Where those products are prescription-only therapeutic goods, this type of advertising is non-compliant.

Cosmetic clinics should review their marketing for any content that names specific prescription products, makes claims about what specific products can achieve, or attributes treatment outcomes to particular therapeutic goods rather than to the overall treatment and practitioner skill.

Listed Medicine Advertising

Listed medicines (those with an AUST L number) can be advertised to consumers, but that advertising must comply with the Therapeutic Goods Advertising Code. This priority area reflects ongoing concerns about listed medicine advertising that makes claims beyond what is permitted.

Common compliance issues include claims that are not consistent with the product's listing on the Australian Register of Therapeutic Goods (ARTG), use of restricted representations without approval, inadequate mandatory statements in advertising, and social media and influencer content that makes claims the advertiser could not make directly.

For businesses that manufacture, distribute, or retail listed medicines, this is a reminder to audit all advertising touchpoints, including social media, e-commerce listings, website content, and any influencer or affiliate arrangements.

Digital Marketing Under the Microscope

A consistent thread running through the TGA's 2026-2027 priorities is the focus on digital channels. The regulator has clearly recognised that the majority of non-compliant therapeutic goods advertising now occurs online, and it is building the tools and processes to address this.

Social Media Compliance

Social media platforms present unique compliance challenges because content is created quickly, often informally, and may not go through the same review processes as traditional advertising. The TGA's increased focus on social media means healthcare businesses need to treat every social media post with the same compliance rigour as a print advertisement or website page.

Key areas of risk on social media include posts that make therapeutic claims about products without required disclaimers, sharing user-generated content that endorses therapeutic goods, stories or reels featuring products with implied or stated health benefits, comments and replies that make claims about product efficacy, and hashtag strategies that associate products with specific health conditions.

Influencer and Affiliate Content

The TGA has specifically called out influencer content in multiple compliance principles. This is not surprising given the prevalence of influencer marketing in health and wellness categories.

The regulatory position is clear: if an influencer is paid, gifted products, or otherwise compensated to promote therapeutic goods, the resulting content must comply with the same advertising rules that would apply if the business published that content directly. The business engaging the influencer bears responsibility for ensuring compliance.

Practically, this means businesses should have written agreements with influencers that specify compliance requirements, review and approve all content before publication, ensure influencers disclose the commercial nature of their content, avoid arrangements where influencers make claims the business itself could not make, and maintain records of all influencer arrangements and content approvals.

AI-Generated Content Risks

The TGA's explicit mention of AI-generated misinformation is forward-looking and reflects the reality that many businesses now use AI tools to create marketing content. While AI tools can improve efficiency, they introduce specific compliance risks.

AI language models can generate plausible-sounding health claims that have no evidence base, invent clinical studies or statistics, fail to include required disclaimers or mandatory statements, use language that crosses regulatory boundaries (such as implying guaranteed outcomes), and produce content that conflates different regulatory categories (such as treating a listed medicine as if it were an approved therapeutic).

Healthcare businesses using AI for content creation should implement mandatory human review of all AI-generated content before publication, with reviewers who understand TGA advertising requirements. AI is a drafting tool, not a compliance officer.

Google Ads and Paid Search

While the TGA's priorities do not specifically name Google Ads, paid search advertising falls squarely within the scope of digital advertising scrutiny. Healthcare businesses running Google Ads campaigns for therapeutic goods need to ensure their ad copy does not make non-compliant claims, their landing pages comply with TGA advertising requirements, they are not advertising prescription-only medicines to consumers, and their keyword targeting does not effectively circumvent advertising restrictions.

Google itself has healthcare advertising policies that add another layer of requirements, but compliance with Google's policies does not guarantee compliance with TGA regulations. The two frameworks are separate, and healthcare businesses must satisfy both.

Other Active Compliance Programs

Beyond the 12 priority focus areas, the TGA maintains several ongoing compliance programs that healthcare businesses should be aware of. These are not on the priority list for 2026-2027, but they remain active regulatory programs.

• Complementary medicine listings: ongoing review of products listed on the ARTG, including verification that listed indications are supported by evidence
• Medical device post-market reviews: monitoring of medical devices after they enter the Australian market
• Pharmacovigilance and good clinical practice inspections: ongoing programs ensuring adverse event reporting and clinical trial compliance
• GMP compliance: manufacturing standards compliance for therapeutic goods produced in or imported to Australia
• Software and AI medical device compliance: a growing area as more health-related software products meet the definition of medical devices

For healthcare businesses, the software and AI medical device compliance program is worth watching. As health apps, diagnostic tools, and clinical decision support systems proliferate, the boundary between general wellness software and regulated medical devices continues to be defined and refined.

Practical Steps for Healthcare Businesses

Understanding the TGA's compliance priorities is important, but translating that understanding into action is what protects your business. Here are practical steps healthcare businesses should be taking now.

Audit Your Digital Presence

Conduct a thorough review of all your digital marketing touchpoints. This includes your website content, particularly any pages that discuss specific therapeutic goods. Review your social media profiles and recent posts for claims that might not comply with TGA advertising requirements. Check your Google Ads campaigns for ad copy that makes therapeutic claims. Review e-commerce listings if you sell therapeutic goods through online marketplaces. Examine any email marketing content that references therapeutic goods.

Look specifically for claims about product efficacy that are not supported by the product's ARTG listing, before-and-after content that attributes results to specific therapeutic goods, content that effectively advertises prescription-only products to consumers, and missing mandatory statements or disclaimers.

Review Influencer and Affiliate Arrangements

If your business works with influencers, brand ambassadors, or affiliates, review those arrangements against the TGA's stated priorities. Ensure you have documented agreements that include compliance requirements. Review all published influencer content for TGA compliance. Implement a pre-publication approval process for future content. Confirm that commercial relationships are properly disclosed. Consider whether any existing content needs to be modified or removed.

Implement AI Content Review Processes

If your business uses AI tools to generate marketing content, establish a formal review process. Designate a compliance reviewer for all AI-generated content. Create a checklist of TGA advertising requirements specific to your products. Never publish AI-generated health or product claims without human verification. Keep records of your review process as evidence of compliance efforts.

Train Your Team

Everyone involved in creating marketing content for your business should understand the basics of TGA advertising requirements. This includes marketing staff, social media managers, external agencies, and any team members who might create content informally (such as practitioners posting on practice social media accounts).

Training does not need to be exhaustive, but it should cover the fundamental principles: what can and cannot be said about your products, the difference between educational content and advertising, the rules around prescription medicine advertising, and the requirements for any influencer or endorsement arrangements.

Document Your Compliance Efforts

If the TGA does investigate your advertising, being able to demonstrate that you have taken compliance seriously can influence the outcome. Maintain records of content review processes, compliance training, influencer agreements, and any corrective actions you have taken.

What This Means for Healthcare Marketing Agencies

For agencies that work with healthcare businesses, these TGA priorities reinforce the need for specialist knowledge. Generic marketing agencies may not be equipped to navigate the intersection of TGA regulations, AHPRA guidelines, and platform-specific healthcare advertising policies that govern how therapeutic goods can be marketed in Australia.

Healthcare businesses should ensure their marketing partners understand TGA advertising requirements for the specific product categories they work with, can identify compliance risks before content is published, have processes for reviewing content against regulatory requirements, and stay current with evolving TGA guidance and enforcement trends.

Looking Ahead

The TGA's 2026-2027 compliance priorities represent a clear escalation in the regulator's attention to digital marketing of therapeutic goods. The combination of proactive monitoring, enhanced digital capability, and a commitment to visible enforcement actions creates an environment where non-compliant advertising carries more risk than ever before.

For healthcare businesses, the response should not be to retreat from digital marketing. Digital channels remain the most effective way to reach and educate patients and consumers. The response should be to ensure your marketing is built on a foundation of compliance, with proper review processes, clear understanding of what can and cannot be said, and marketing partners who understand the regulatory landscape.

The businesses that get this right will have a genuine competitive advantage. When competitors are pulled up for non-compliant advertising, the businesses that have invested in doing things properly will be the ones still operating, still visible, and still building trust with their audiences.

If you are unsure whether your current marketing complies with the TGA's requirements, or if you want to develop marketing strategies that work effectively within the regulatory framework, that is exactly the kind of challenge we work on every day. We are always happy to have a conversation about what compliant healthcare marketing looks like for your specific situation.